Whole‐body MRI including diffusion‐weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI

Abstract

In patients with recurrent prostate cancer a whole-body MR protocol including DWI is technically robust. Due to the high CNR of DWI compared to T1w and T2w STIR, detection of malignant lesions should be facilitated by DWI, except for sclerotic bone metastases.